News coverage about RadNet (NASDAQ:RDNT) has been trending somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. RadNet earned a news impact score of 0.24 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 45.9758504349527 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the media stories that may have effected Accern Sentiment’s analysis:
- RadNet (RDNT) versus The Competition Head to Head Review (americanbankingnews.com)
- RadNet (RDNT) Stock Rating Lowered by Zacks Investment Research (americanbankingnews.com)
- RadNet, Inc. (RDNT) year to date performance remained at 37.13% (nasdaqfortune.com)
- Investors Purchase High Volume of RadNet Put Options (RDNT) (americanbankingnews.com)
- RadNet Target of Unusually Large Options Trading (RDNT) (americanbankingnews.com)
Shares of RDNT opened at $14.40 on Monday. RadNet has a 1-year low of $5.40 and a 1-year high of $14.45. The firm has a market capitalization of $694.54, a P/E ratio of 49.66, a P/E/G ratio of 3.33 and a beta of 0.38. The company has a debt-to-equity ratio of 8.22, a current ratio of 1.23 and a quick ratio of 1.23.
A number of brokerages recently weighed in on RDNT. BidaskClub raised shares of RadNet from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 23rd. FIX began coverage on shares of RadNet in a research report on Wednesday, March 14th. They issued a “strong-buy” rating and a $15.00 price target for the company. Zacks Investment Research cut shares of RadNet from a “buy” rating to a “hold” rating in a research report on Friday, March 23rd. Raymond James Financial began coverage on shares of RadNet in a research report on Wednesday, March 14th. They issued a “strong-buy” rating and a $15.00 price target for the company. Finally, Jefferies Group set a $14.00 price target on shares of RadNet and gave the company a “buy” rating in a research report on Thursday, March 8th. One equities research analyst has rated the stock with a hold rating, one has issued a buy rating and three have assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $14.50.
In other RadNet news, VP Mark Stolper sold 15,000 shares of RadNet stock in a transaction on Tuesday, March 20th. The shares were sold at an average price of $13.19, for a total value of $197,850.00. Following the transaction, the vice president now directly owns 130,319 shares in the company, valued at $1,718,907.61. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Jeffrey L. Linden sold 10,000 shares of RadNet stock in a transaction on Wednesday, March 14th. The shares were sold at an average price of $13.09, for a total transaction of $130,900.00. Following the completion of the transaction, the insider now owns 922,001 shares in the company, valued at $12,068,993.09. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 108,927 shares of company stock worth $1,405,852. 9.36% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION WARNING: This piece was reported by WKRB News and is the sole property of of WKRB News. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.wkrb13.com/2018/04/02/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-radnet-rdnt-share-price.html.
RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.
Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.